| Year |
Citation |
Score |
| 2020 |
Valentinuzzi D, Vrankar M, Boc N, Ahac V, Zupancic Z, Unk M, Skalic K, Zagar I, Studen A, Simoncic U, Eickhoff J, Jeraj R. [18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab. Radiology and Oncology. 54: 285-294. PMID 32726293 DOI: 10.2478/Raon-2020-0042 |
0.304 |
|
| 2020 |
Uboha NV, Lubner SJ, LoConte NK, Mulkerin DL, Eickhoff JC, Deming DA. Phase 1 dose escalation trial of TAS-102 (trifluridine/tipiracil) and temozolomide in the treatment of advanced neuroendocrine tumors. Investigational New Drugs. PMID 32253554 DOI: 10.1007/S10637-020-00929-Y |
0.327 |
|
| 2020 |
Uboha NV, Eickhoff JC, Chandrasekharan C, Jalal SI, Benson AB, Deming DA, Lindemann S, Hochster HS. Phase II study of the combination of abemaciclib and pembrolizumab in locally advanced unresectable or metastatic gastroesophageal adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149. Journal of Clinical Oncology. 38: TPS461-TPS461. DOI: 10.1200/Jco.2020.38.4_Suppl.Tps461 |
0.347 |
|
| 2020 |
Uboha NV, Lubner SJ, LoConte NK, Mulkerin D, Eickhoff JC, Deming DA. Phase I dose-escalation trial of trifluridine/tipiracil (TAS-102) and temozolomide in the treatment of advanced neuroendocrine tumors. Journal of Clinical Oncology. 38: 615-615. DOI: 10.1200/Jco.2020.38.4_Suppl.615 |
0.338 |
|
| 2020 |
Deming DA, Emmerich P, Turk AA, Lubner SJ, Uboha NV, LoConte NK, Mulkerin D, Kim DH, Matkowskyj KA, Weber SM, Abbott D, Eickhoff JC, Bassetti MF. Pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver oligometastatic MSS/MMR proficient colorectal cancer (CRC). Journal of Clinical Oncology. 38: 4046-4046. DOI: 10.1200/Jco.2020.38.15_Suppl.4046 |
0.312 |
|
| 2019 |
Uboha NV, Maloney JD, McCarthy D, Deming DA, LoConte NK, Matkowskyj K, Eickhoff JC, Mulkerin D, DeCamp MM, Lubner SJ, Turk AA, Bassetti MF. Phase I/II trial of perioperative avelumab in combination with chemoradiation in the treatment of stage II/III resectable esophageal cancer. Journal of Clinical Oncology. 37: TPS181-TPS181. DOI: 10.1200/Jco.2019.37.4_Suppl.Tps181 |
0.346 |
|
| 2019 |
Turk AA, Lubner SJ, Uboha NV, LoConte NK, Mulkerin D, Kim DH, Matkowskyj K, Weber SM, Abbott D, Eickhoff JC, Bassetti MF, Deming DA. A phase Ib study of pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver metastatic colorectal cancer (CRC). Journal of Clinical Oncology. 37: 680-680. DOI: 10.1200/Jco.2019.37.4_Suppl.680 |
0.323 |
|
| 2019 |
Bassetti MF, Turk AA, Lubner SJ, Uboha NV, LoConte NK, Mulkerin D, Kim DH, Matkowskyj K, Weber SM, Abbott D, Eickhoff JC, Deming DA. A phase Ib study of pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver metastatic MSS colorectal cancer (CRC): A postoperative safety analysis. Journal of Clinical Oncology. 37: e15047-e15047. DOI: 10.1200/Jco.2019.37.15_Suppl.E15047 |
0.323 |
|
| 2019 |
Liu G, Fong L, Antonarakis ES, Eickhoff JC, Wargowski EG, Johnson LE, Jeraj R, McNeel DG. Randomized phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) versus GM-CSF adjuvant in patients with PSA-recurrent prostate cancer. Journal of Clinical Oncology. 37: 5037-5037. DOI: 10.1200/Jco.2019.37.15_Suppl.5037 |
0.317 |
|
| 2019 |
Uboha NV, Maloney JD, McCarthy D, Deming DA, LoConte NK, Matkowskyj K, Eickhoff JC, Emmerich P, DeCamp MM, Lubner SJ, Turk AA, Bassetti MF. Safety of neoadjuvant chemoradiation (CRT) in combination with avelumab (A) in the treatment of resectable esophageal and gastroesophageal junction (E/GEJ) cancer. Journal of Clinical Oncology. 37: 4041-4041. DOI: 10.1200/Jco.2019.37.15_Suppl.4041 |
0.316 |
|
| 2018 |
McNeel DG, Eickhoff JC, Wargowski E, Zahm C, Staab MJ, Straus J, Liu G. Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer. Oncotarget. 9: 25586-25596. PMID 29876010 DOI: 10.18632/Oncotarget.25387 |
0.319 |
|
| 2018 |
Deming DA, Kim DH, Matkowskyj K, Uboha NV, Lubner SJ, LoConte NK, Mulkerin D, Abbott D, Weber SM, Winslow E, Jeraj R, Ritter MA, Perlman S, Eickhoff JC, Bassetti MF. Keynote 290: Pembrolizumab (pem) in combination with stereotactic body radiotherapy for resectable liver metastatic colorectal cancer. Journal of Clinical Oncology. 36: TPS874-TPS874. DOI: 10.1200/Jco.2018.36.4_Suppl.Tps874 |
0.325 |
|
| 2018 |
Uboha NV, Deming DA, Lubner SJ, Mulkerin D, Eickhoff JC, LoConte NK. Safety of trifluridine/tipiracil (TAS-102) in combination with temozolomide for metastatic neuroendocrine tumors. Journal of Clinical Oncology. 36: TPS549-TPS549. DOI: 10.1200/Jco.2018.36.4_Suppl.Tps549 |
0.35 |
|
| 2018 |
Turk AA, Deming DA, Lubner SJ, Mulkerin D, LoConte NK, Tevaarwerk A, Wisinski KB, Eickhoff JC, Liu G. A phase I study of veliparib (Vel) in combination with oxaliplatin (Ox) and capecitabine (Cap) in advanced solid tumors. Journal of Clinical Oncology. 36: 314-314. DOI: 10.1200/Jco.2018.36.4_Suppl.314 |
0.323 |
|
| 2017 |
McNeel DG, Eickhoff JC, Jeraj R, Staab MJ, Straus J, Rekoske B, Liu G. DNA vaccine with pembrolizumab to elicit antitumor responses in patients with metastatic, castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 35: 168-168. DOI: 10.1200/Jco.2017.35.7_Suppl.168 |
0.316 |
|
| 2017 |
Turk A, Chan N, Leal T, O'Regan R, Tevaarwerk A, Rice L, Campbell T, Barroilhet L, Mehnert J, Eickhoff J, Kolesar J, Liu G, Wisinski K. Abstract P4-22-21: NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P4-22-21 |
0.323 |
|
| 2016 |
Kyriakopoulos CE, Braden AM, Kolesar JM, Eickhoff JC, Bailey HH, Heideman J, Liu G, Wisinski KB. A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors. Investigational New Drugs. PMID 28004284 DOI: 10.1007/S10637-016-0418-8 |
0.315 |
|
| 2016 |
Mullvain J, Leal T, Eickhoff J, Kolesar J, Liu G, DiPaola R, Wisinski K. Abstract OT3-02-06: A phase 1 study of BMN 673 in combination with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782) Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-Ot3-02-06 |
0.347 |
|
| 2015 |
Makielski RJ, Lubner SJ, Mulkerin DL, Traynor AM, Groteluschen D, Eickhoff J, LoConte NK. A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer. Cancer Chemotherapy and Pharmacology. 76: 317-23. PMID 26068189 DOI: 10.1007/S00280-015-2783-Y |
0.302 |
|
| 2015 |
LoConte NK, Razak AR, Ivy P, Tevaarwerk A, Leverence R, Kolesar J, Siu L, Lubner SJ, Mulkerin DL, Schelman WR, Deming DA, Holen KD, Carmichael L, Eickhoff J, Liu G. A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Investigational New Drugs. 33: 169-76. PMID 25318436 DOI: 10.1007/S10637-014-0166-6 |
0.303 |
|
| 2015 |
Kyriakopoulos C, Heath EI, Eickhoff JC, Kolesar J, Yayehyirad M, Moll T, Liu G. Phase 1/2a, open-label, dose-escalation and safety study of APC-100 in men with advanced prostate cancer. Journal of Clinical Oncology. 33: 234-234. DOI: 10.1200/Jco.2015.33.7_Suppl.234 |
0.301 |
|
| 2015 |
Kyriakopoulos C, Kolesar J, Eickhoff JC, Heideman J, Liu G, Wisinski KB. A phase I study of ARQ 197 in combination with temsirolimus in advanced solid tumors. Journal of Clinical Oncology. 33: 2554-2554. DOI: 10.1200/Jco.2015.33.15_Suppl.2554 |
0.313 |
|
| 2015 |
Nazeef M, Tevaarwerk AJ, Eickhoff J, Burkard ME, Heideman J, Liu G, Flynn C, Kolesar JM, Wisinski KB. Abstract P5-19-20: A phase I study of MK-2206 in combination with lapatinib in patients with advanced solid tumors followed by dose-expansion in advanced HER2+ breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P5-19-20 |
0.337 |
|
| 2014 |
Deming DA, Ninan J, Bailey HH, Kolesar JM, Eickhoff J, Reid JM, Ames MM, McGovern RM, Alberti D, Marnocha R, Espinoza-Delgado I, Wright J, Wilding G, Schelman WR. A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. Investigational New Drugs. 32: 323-9. PMID 24114123 DOI: 10.1007/S10637-013-0035-8 |
0.31 |
|
| 2014 |
Schelman WR, Mohammed TA, Traynor AM, Kolesar JM, Marnocha RM, Eickhoff J, Keppen M, Alberti DB, Wilding G, Takebe N, Liu G. A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer. Investigational New Drugs. 32: 295-302. PMID 23860642 DOI: 10.1007/S10637-013-9999-7 |
0.328 |
|
| 2014 |
Braden AM, Wisinski KB, Eickhoff JC, Schelman WR, Bailey HH, Mulkerin D, Heideman J, Kolesar J, Liu G. A phase I study of ARQ 197 in combination with temsirolimus in patients (Pts) with advanced solid tumors. Journal of Clinical Oncology. 32: 2555-2555. DOI: 10.1200/Jco.2014.32.15_Suppl.2555 |
0.31 |
|
| 2013 |
Schelman WR, Traynor AM, Holen KD, Kolesar JM, Attia S, Hoang T, Eickhoff J, Jiang Z, Alberti D, Marnocha R, Reid JM, Ames MM, McGovern RM, Espinoza-Delgado I, Wright JJ, et al. A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. Investigational New Drugs. 31: 1539-46. PMID 24114121 DOI: 10.1007/S10637-013-0029-6 |
0.319 |
|
| 2013 |
Cetnar J, Wilding G, McNeel D, LoConte NK, McFarland TA, Eickhoff J, Liu G. A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer. Urologic Oncology. 31: 436-41. PMID 21481618 DOI: 10.1016/J.Urolonc.2011.02.007 |
0.316 |
|
| 2013 |
King JD, Retseck J, Eickhoff JC, Hoang T, Traynor AM, Campbell TC. Integrated oncopalliative care versus standard care for patients with metastatic lung cancer: A single institution retrospective review. Journal of Clinical Oncology. 31: 9566-9566. DOI: 10.1200/Jco.2013.31.15_Suppl.9566 |
0.307 |
|
| 2013 |
Wisinski KB, Tevaarwerk A, Bell M, Burkard ME, Eickhoff JC, Wilding G, LoConte NK, Traynor AM, Hoang T, Heideman J, Kolesar J, Liu G. A phase I study of MK-2206 in combination with lapatinib in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 31: 2607-2607. DOI: 10.1200/Jco.2013.31.15_Suppl.2607 |
0.302 |
|
| 2012 |
Albertini MR, Hank JA, Gadbaw B, Kostlevy J, Haldeman J, Schalch H, Gan J, Kim K, Eickhoff J, Gillies SD, Sondel PM. Phase II trial of hu14.18-IL2 for patients with metastatic melanoma. Cancer Immunology, Immunotherapy : Cii. 61: 2261-71. PMID 22678096 DOI: 10.1007/S00262-012-1286-5 |
0.316 |
|
| 2012 |
McNeel DG, Smith HA, Eickhoff JC, Lang JM, Staab MJ, Wilding G, Liu G. Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunology, Immunotherapy : Cii. 61: 1137-47. PMID 22210552 DOI: 10.1007/S00262-011-1193-1 |
0.345 |
|
| 2012 |
Tevaarwerk A, Wilding G, Eickhoff J, Chappell R, Sidor C, Arnott J, Bailey H, Schelman W, Liu G. Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design. Investigational New Drugs. 30: 1039-45. PMID 21225315 DOI: 10.1007/S10637-010-9629-6 |
0.305 |
|
| 2012 |
Cleary JF, Cannon GM, Eickhoff JC, Thunberg AL, Fahl WE. Radioprotection study of topical norepinephrine in postsurgical breast cancer patients. Journal of Clinical Oncology. 30: TPS9152-TPS9152. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps9152 |
0.309 |
|
| 2012 |
Deming DA, Schelman WR, Lubner SJ, Mulkerin D, LoConte NK, Fioravanti S, Greten T, Eickhoff JC, Kolesar J, Compton K, Doyle LA, Wilding G, Duffy AG, Liu G. A phase I study of selumetinib (AZD6244/ARRY-142866) in combination with cetuximab (cet) in refractory solid tumors and KRAS mutant colorectal cancer (CRC). Journal of Clinical Oncology. 30: 3103-3103. DOI: 10.1200/Jco.2012.30.15_Suppl.3103 |
0.306 |
|
| 2012 |
LoConte NK, Tevaarwerk A, Kolesar J, Holen KD, Lubner SJ, Mulkerin D, Schelman WR, Razak ARA, Siu LL, Eickhoff JC, Carmichael L, Wilding G, Ivy SP, Liu G. A phase I study of the gamma-secretase inhibitor RO4929097 and capecitabine in refractory solid tumors. Journal of Clinical Oncology. 30: 3101-3101. DOI: 10.1200/Jco.2012.30.15_Suppl.3101 |
0.301 |
|
| 2011 |
Chang JE, Peterson C, Choi S, Eickhoff JC, Kim K, Yang DT, Gilbert LA, Rogers ES, Werndli JE, Huie MS, McFarland TA, Volk M, Blank J, Callander NS, Longo WL, et al. VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. British Journal of Haematology. 155: 190-7. PMID 21848883 DOI: 10.1111/J.1365-2141.2011.08820.X |
0.321 |
|
| 2010 |
Lubner SJ, Loconte NK, Holen KD, Schelman W, Thomas JP, Jumonville A, Eickhoff JC, Seo S, Mulkerin DL. A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer. Clinical Colorectal Cancer. 9: 157-61. PMID 20643620 DOI: 10.3816/Ccc.2010.N.021 |
0.316 |
|
| 2010 |
Leal TA, Schelman WR, Traynor AM, Kolesar J, Marnocha RM, Eickhoff JC, Alberti DB, Takebe N, Wilding G. A phase I study of r-(-)-gossypol (AT-101, NSC 726190) in combination with cisplatin (P) and etoposide (E) in patients with advanced solid tumors and extensive-stage small cell lung cancer (ES-SCLC). Journal of Clinical Oncology. 28: e13030-e13030. DOI: 10.1200/Jco.2010.28.15_Suppl.E13030 |
0.331 |
|
| 2010 |
Lepeak LM, Wilding G, Eickhoff JC, Chappell R, Sidor C, Arnott J, Jeraj R, Perlman S, Liu G, Tevaarwerk A. Phase I study of continuous MKC-1 (cMKC-1) in patients (pts) with advanced or metastatic solid malignancies using a modified time-to-event continual reassessment method (TITE-CRM) for dose assignment. Journal of Clinical Oncology. 28: e13001-e13001. DOI: 10.1200/Jco.2010.28.15_Suppl.E13001 |
0.304 |
|
| 2009 |
Schelman WR, Morgan-Meadows S, Marnocha R, Lee F, Eickhoff J, Huang W, Pomplun M, Jiang Z, Alberti D, Kolesar JM, Ivy P, Wilding G, Traynor AM. A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 63: 1147-56. PMID 19082825 DOI: 10.1007/S00280-008-0890-8 |
0.309 |
|
| 2008 |
Liu G, Kolesar J, McNeel DG, Leith C, Schell K, Eickhoff J, Lee F, Traynor A, Marnocha R, Alberti D, Zwiebel J, Wilding G. A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2732-9. PMID 18451239 DOI: 10.1158/1078-0432.Ccr-07-1490 |
0.315 |
|
| 2008 |
LoConte NK, Thomas JP, Alberti D, Heideman J, Binger K, Marnocha R, Utecht K, Geiger P, Eickhoff J, Wilding G, Kolesar J. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 63: 109-15. PMID 18322686 DOI: 10.1007/S00280-008-0719-5 |
0.329 |
|
| 2008 |
Attia S, Kolesar J, Mahoney MR, Pitot HC, Laheru D, Heun J, Huang W, Eickhoff J, Erlichman C, Holen KD. A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. Investigational New Drugs. 26: 369-79. PMID 18278438 DOI: 10.1007/S10637-008-9123-6 |
0.348 |
|
| 2008 |
Schelman W, Morgan-Meadows S, Bailey H, Holen K, Thomas JP, Eickhoff J, Brandon H, Oliver K, Alberti D, Wilding G. A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 62: 727-33. PMID 18172649 DOI: 10.1007/S00280-007-0656-8 |
0.32 |
|
| 2008 |
Leal TB, Wilding G, Eickhoff J, McNeel D, Alberti D, Liu G. Phase I study of satraplatin and docetaxel in solid malignancies Journal of Clinical Oncology. 26: 2570-2570. DOI: 10.1200/Jco.2008.26.15_Suppl.2570 |
0.316 |
|
| 2008 |
Kahl B, Chang J, Eickhoff J, Gilbert L, Rogers E, Werndli J, Huie M, McFarland T, Volk M, Blank JH, Callander N, Longo W, Peterson C. VcR-CVAD Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma: A Phase II Study from the Wisconsin Oncology Network Blood. 112: 265-265. DOI: 10.1182/Blood.V112.11.265.265 |
0.316 |
|
| 2007 |
Kujawski LA, Longo WL, Williams EC, Turman NJ, Brandt N, Mosher DF, Eickhoff JC, Kahl BS. A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas. Cancer Investigation. 25: 87-93. PMID 17453819 DOI: 10.1080/07357900701205507 |
0.325 |
|
| 2007 |
Schelman WR, Kolesar J, Schell K, Marnocha R, Eickhoff J, Alberti D, Wilding G, Bailey H. A phase I study of vorinostat in combination with bortezomib in refractory solid tumors Journal of Clinical Oncology. 25: 3573-3573. DOI: 10.1200/Jco.2007.25.18_Suppl.3573 |
0.319 |
|
| 2007 |
LoConte NK, Holen KD, Eickhoff J, Dzelak T, Richie K, Teeter K, Warren D, Jumonville AJ, Kwong RW, Mulkerin DL. A multicenter phase 2 clinical trial testing a combination of oxaliplatin, bolus 5-fluorouracil, leucovorin and capecitabine in patients with metastatic colorectal cancer (MCRC) Journal of Clinical Oncology. 25: 14526-14526. DOI: 10.1200/Jco.2007.25.18_Suppl.14526 |
0.338 |
|
| 2006 |
Meadows SM, Ummersen LV, Brandon H, Oliver K, Houston M, Eickhoff J, Wilding G. A dose escalation trial of fixed dose gemcitabine and capecitabine Journal of Clinical Oncology. 24: 12026-12026. DOI: 10.1200/Jco.2006.24.18_Suppl.12026 |
0.301 |
|
| 2006 |
Schelman WR, Holen K, Mulkerin D, Kolesar J, Thomas J, Kruse M, Oliver K, Marnocha R, Eickhoff J, Wilding G. A phase I study of triapine in combination with irinotecan in refractory tumors Journal of Clinical Oncology. 24: 12011-12011. DOI: 10.1200/Jco.2006.24.18_Suppl.12011 |
0.315 |
|
| 2005 |
Eickhoff JC, Amemiya Y. Latent variable models for misclassified polytomous outcome variables. The British Journal of Mathematical and Statistical Psychology. 58: 359-75. PMID 16293206 DOI: 10.1348/000711005X64970 |
0.479 |
|
| 2005 |
McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, Friedl A, Kolesar J, Marnocha R, Volkman J, Zhang J, Hammershaimb L, Zwiebel JA, Wilding G. Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 7851-60. PMID 16278408 DOI: 10.1158/1078-0432.Ccr-05-0262 |
0.333 |
|
| 2005 |
Fenske TS, Kahl BS, Eickhoff J, Mitchell TL, Smith EP, Atkinson E, McCoy AG, Eckstein L, Flynn B, McMannes J, Howard S, Longo WL. Excessive toxicity of the high dose thiotepa and etoposide regimen when combined with radiation: Long-term autologous transplantation experience in follicular and mantle cell lymphoma. Leukemia & Lymphoma. 46: 1441-8. PMID 16194889 DOI: 10.1080/10428190500144656 |
0.306 |
|
| 2005 |
Eickhoff JC, Amemiya Y. Generalized linear latent variable modeling for multi-group studies Communications in Statistics - Theory and Methods. 34: 1991-2008. DOI: 10.1080/03610920500203109 |
0.502 |
|
| 2004 |
King DM, Albertini MR, Schalch H, Hank JA, Gan J, Surfus J, Mahvi D, Schiller JH, Warner T, Kim K, Eickhoff J, Kendra K, Reisfeld R, Gillies SD, Sondel P. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 4463-73. PMID 15483010 DOI: 10.1200/Jco.2004.11.035 |
0.309 |
|
| 2004 |
Kahl BS, McGovern J, Blank J, Jaslowski A, Bayer G, Bottner WA, Rezazadeh H, McFarland T, Hei D, Smith J, Stevens EA, Eickhoff JC, Longo WL. Phase II Study of Modified Hyper-CVAD with Rituximab Maintenance for Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study. Blood. 104: 1388-1388. DOI: 10.1182/Blood.V104.11.1388.1388 |
0.322 |
|
| 2004 |
Eickhoff JC, Zhu J, Amemiya Y. On the simulation size and the convergence of the Monte Carlo EM algorithm via likelihood-based distances Statistics and Probability Letters. 67: 161-171. DOI: 10.1016/J.Spl.2004.01.004 |
0.481 |
|
| Show low-probability matches. |